Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells 920 Shares of Stock

Key Points

• BeOne Medicines Ltd. SVP Chan Henry Lee sold 920 shares of the company's stock at an average price of $304.60, totaling $280,232.
• The company's stock experienced a 0.4% increase on the day of the sale, reaching $301.13, with a trading volume surpassing its average.
• Wall Street analysts have raised their price targets for BeOne Medicines, with recent estimates ranging from $330 to $350, while the stock currently has an overall "buy" rating.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 920 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $304.60, for a total transaction of $280,232.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 16th, Chan Henry Lee sold 422 shares of BeOne Medicines stock. The shares were sold at an average price of $266.50, for a total transaction of $112,463.00.
• On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00.

BeOne Medicines Trading Up 0.4%

ONC stock traded up $1.19 on Thursday, hitting $301.13. The company's stock had a trading volume of 503,014 shares, compared to its average volume of 438,001. The firm's 50 day simple moving average is $261.59. BeOne Medicines Ltd. - Sponsored ADR has a 1 year low of $155.75 and a 1 year high of $308.87. The stock has a market capitalization of $33.00 billion, a PE ratio of -80.95 and a beta of 0.28. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ONC. Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $311.00 to $349.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Morgan Stanley upped their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, June 27th. TD Securities restated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a report on Thursday, April 24th. Guggenheim upped their target price on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines has a consensus rating of "Buy" and a consensus target price of $327.56.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. purchased a new position in BeOne Medicines during the 2nd quarter worth $7,150,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $28,000. Asset Management One Co. Ltd. purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $4,951,000. FNY Investment Advisers LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $121,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $3,289,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.